- Home
- LLY
as 11-14-2025 3:39pm EST
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
| Founded: | 1876 | Country: | United States |
| Employees: | N/A | City: | INDIANAPOLIS |
| Market Cap: | 716.8B | IPO Year: | N/A |
| Target Price: | $1020.06 | AVG Volume (30 days): | 4.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 20.44 | EPS Growth: | 121.02 |
| 52 Week Low/High: | $623.78 - $1033.62 | Next Earning Date: | 10-30-2025 |
| Revenue: | $59,419,800,000 | Revenue Growth: | 45.41% |
| Revenue Growth (this year): | 40.23% | Revenue Growth (next year): | 18.67% |
Stock Insider Trading Activity of Eli Lilly and Company (LLY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | LLY | 10% Owner | Nov 13 '25 | Sell | $1,030.99 | 46,606 | $48,016,098.38 | 93,061,732 | |
| Zakrowski Donald A | LLY | SVP, Finance, & CAO | Nov 13 '25 | Sell | $1,010.50 | 1,000 | $1,010,500.00 | 2,839.659 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Nov 12 '25 | Sell | $1,011.53 | 305,000 | $308,411,204.36 | 93,061,732 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Nov 11 '25 | Sell | $985.92 | 283,131 | $279,347,679.79 | 93,061,732 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Nov 10 '25 | Sell | $973.29 | 16,869 | $16,405,395.92 | 93,061,732 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Nov 5 '25 | Sell | $935.31 | 219,474 | $205,565,546.07 | 93,061,732 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Nov 4 '25 | Sell | $910.72 | 526 | $479,038.19 | 93,061,732 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Nov 3 '25 | Sell | $889.35 | 300,000 | $266,648,920.78 | 93,061,732 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Oct 31 '25 | Sell | $866.02 | 301,342 | $260,165,030.94 | 93,061,732 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Oct 10 '25 | Sell | $862.85 | 3,658 | $3,157,722.23 | 93,061,732 |
Latest Eli Lilly and Company News
LLY Breaking Stock News: Dive into LLY Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Eli Lilly’s (LLY) “a Great Company,” Says Jim Cramer
24/7 Wall St.
a day ago
Alphabet’s Secret Portfolio Just Bought These 2 Stocks. Should You Buy Too?
Investing.com
2 days ago
Investing.com’s stocks of the week
Simply Wall St.
2 days ago
Eli Lilly (LLY): Evaluating Valuation as Growth Momentum Builds
24/7 Wall St.
2 days ago
Retail Investors Really Don’t Like Novo Nordisk (NVO) Stock
The Wall Street Journal
2 days ago
Stocks to Watch Recap: Alphabet, Walmart, Eli Lilly, Warner Bros.
MT Newswires
2 days ago
S&P 500 Posts Slight Weekly Rise, Led by Health Care, Energy
Pharmaceutical Technology
2 days ago
Raising the bar: can higher drug spending in the UK deliver for pharma and patients?
Compare LLY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LLY Eli Lilly and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.